** Hong Kong-listed shares of Chinese oncology treatments developer Beigene Ltd 6160.HK jump 10.1% to HK$117.40

** Stock marks biggest intraday pct rise since December 2022

** Stock hits the highest point since Dec 10, and on course to snap two sessions of decline, if gains hold; stock is fourth-biggest pct gainer in Hang Seng Composite Index .HSCI, which adds 0.9%

** Beigene says it expects to achieve "positive" operating income for full-year 2025 pursuant to U.S. generally accepted accounting principles

** Beigene's Shanghai stock 688235.SS surges 6.7% to 174.18 yuan, its highest since Dec 10

** Hang Seng Commerce & Industry Index .HSNC rises 1.1%, healthcare index .HSCIH surges 2.4% and Hang Seng Index .HSI gains 0.9%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))